We're currently experiencing extremely high call volumes. We're very sorry for any inconvenience this might cause. If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Fennec Pharmaceuticals Inc (FRX) NPV

Sell:8.85 CAD Buy:9.14 CAD Change: 0.39 CAD (4.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.85 CAD
Buy:9.14 CAD
Change: 0.39 CAD (4.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:8.85 CAD
Buy:9.14 CAD
Change: 0.39 CAD (4.53%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company's lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children's Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

Contact details

Address:
68 Tw Alexander Dr
PO Box 13628
DURHAM
27709-3628
United States
Telephone:
+1 (919) 6364530
Website:
fennecpharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
FRX
ISIN:
CA31447P1009
Market cap:
177.03 million CAD
Shares in issue:
19.90 million
Sector:
Biotechnology
Exchange:
Toronto Stock Exchange
Country:
Canada
Currency:
Canadian dollars
Indices:
n/a

Key personnel

  • Khalid Islam
    Chairman of the Board
  • Rostislav Raykov
    Chief Executive Officer, Director
  • Robert Andrade
    Chief Financial Officer
  • Shubh Goel
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.